IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: JOHNSON et al.

Art Unit: 1648

Serial No.: 09/158,120

Examiner: Hill, M.

Filed: September 21, 1998

Atty. Docket: RS100CP1D1

For: HUMAN-MURINE CHIMERIC ANTIBODIES AGAINST

RESPIRATORY SYNCYTIAL VIRUS

Statement Regarding Duty to Disclose Information Material To Patentability Under 37 CFR 1.56 and 37 CFR 1.97 (c)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A and SB/08B which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

Please charge the fee of \$180.00 to deposit account number 50-0479. Furthermore, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0479.

Respectfully submitted,

10/29/2004 CNGUYEN 00000125 500479 09158120

02 FC:1806

180.00 DA

Edward I. Amaya, Reg. No.: 54,960

Date: October 19, 2004

MEDIMMUNE, INC.

One MedImmune Way Gaithersburg, Maryland 20878

Tel: 301-398-4129

Fax: 301-398-9280

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Col	mpiete ir Known	•
Application Number	09/158,120	
Filing Date	September 21, 1998	
First Named Inventor	JOHNSON et al.	
Art Unit	1648	
Examiner Name	Hill, M.	
Attorney Docket Number	RS100CP1D1	

Examiner			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.¹	Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	1.	^{US-} 5,225,539		WINTER, Gregory P.	
		US-			
		us-		11 111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
		US-			
		US-			
		US-			
		บร-			
		US-			
	<u> </u>	US-	+		
	-	US-			

FOREIGN PATENT DOCUMENTS						
Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
	Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶	
					<u> </u>	
					╄	
					╄—	
					╆	
					┢	
		No.1 Foreign Patent Document	Cite Foreign Patent Document Publication Date MM-DD-YYYY	Cite Foreign Patent Document Publication Name of Patentee or Date Applicant of Cited Document MM-DD-YYYY	Cite Foreign Patent Document Publication Name of Patentee or Applicant of Cited Document Mhere Relevant Passages MM-DD-YYYY Mmer Relevant Passages Or Relevant Floures Appear	

	
Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

0	Inder the Paperwork Reduction Act of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control nu	umbe
Sub	Dute for form 1449/PTO		Complete if Known	
	5	Application Number	09/158,120	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> 2 of

(Use as many sheets as necessary)

Sheet

Application Number	09/158,120
Filing Date	September 21, 1998
First Named Inventor	JOHNSON et al.
Art Unit	1648
Examiner Name	Hill, M.
Attorney Docket Number	RS100CP1D1

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	MEISSNER et al.: Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody(SB 209763)"; Antimicrobial Agents and Chemotherapy", May 1999,1183-1188 Vol.43, No.5	
	2.	JOHNSON et al.: "A Direct Comparison of the Activities of Two Humanized Respiratiory Syncytial"; The Journal of Infections Diseases; July 1999, p.35-40, Vol. 180, No. 1,	
	3.	WALSH et al.: "Comparison of Antigenic Sites of Subtype-specific Respiratory Syncytial"; Journal of General Virology, July 9,1989, p. 2953-2961, Vol. 70	
	4.	JOHNSON et al.: "Development of a Humanized Monoclonal Antibody (MEDI-493) with Potent In Vitro"; The Journal of Infectious Diseases, November 1997, p.1215-1224, Vol. 176	
	5.	PRINCE et al.: "Quantitative Aspects of Passive Imunity to Respiratory Syncytial Virus Infection in infant"; Journal of Virology, September 1985, p.517-520, Vol.55, No.3	

Signature Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.